Have others tried Capivasertib for estrogen-positive metastatic breast cancer?
Capivasertib (Truqap) combined with fulvestrant was approved in 2023 specifically for HR-positive, HER2-negative breast cancer. It's a serine/threonine kinase inhibitor that may be recommended for people whose breast cancer cells have certain Show Full Answer
Have others tried Capivasertib for estrogen-positive metastatic breast cancer?
Capivasertib (Truqap) combined with fulvestrant was approved in 2023 specifically for HR-positive, HER2-negative breast cancer. It's a serine/threonine kinase inhibitor that may be recommended for people whose breast cancer cells have certain mutations and who've already tried other treatments.
Since you have estrogen-positive metastatic breast cancer that has returned in your liver and bones after previous treatments, Capivasertib could be an appropriate option. It's designed for situations like yours where the cancer has progressed despite trying other therapies.
The approval was based on clinical trials showing effectiveness, though individual responses can vary. It's encouraging that you're exploring newer treatment options after going through multiple treatment iterations.
Switching treatments can feel overwhelming, as one MyBCTeam member shared about having to move on when treatments change. However, there are many treatment options available now for metastatic breast cancer, and finding the right one often involves trying different approaches.
Have you discussed what to expect with this medication with your oncologist? Understanding the potential benefits and side effects can help you feel more prepared as you start this new treatment.
December 8, 2025
Join
Your Privacy Choices
